Navigation Links
Ceregene Announces Clinical Data From Phase 2 Clinical Trial of CERE-120 for Parkinson's Disease
Date:11/26/2008

ibuted to this negative outcome, not only to build upon this insight for our Parkinson's program, but also to help assure continued successful development of our product candidates for other diseases."

About Phase 2 Trial of CERE-120

Ceregene's Phase 2 trial was a double-blind, controlled clinical trial that completed enrollment of 58 patients with advanced Parkinson's disease in November 2007. This study was launched after successful execution of an extensive nonclinical program and preliminary evidence of safety and efficacy in advanced Parkinson's patients via an open-label Phase 1 trial in 12 patients. Patients in the Phase 2 trial were enrolled across nine leading academic medical centers in the United States, with two thirds of patients receiving CERE-120 and one third enrolled into a control group. Patients received a single administration of CERE-120 via stereotactic neurosurgery to deliver the drug into the putamen region of the brain and were followed for 12 months for safety and efficacy.

About CERE-120

CERE-120 is composed of an adeno-associated virus (AAV) vector carrying the gene for neurturin (NTN), a naturally occurring protein known to repair

damaged and dying dopamine-secreting neurons, keeping them alive and restoring normal function. NTN is a member of the same protein family as glial cell-derived neurotrophic factor (GDNF). The two molecules have similar pharmacological properties, and both have been shown to benefit the midbrain dopamine neurons that degenerate in Parkinson's disease and are responsible for the major motor impairments. CERE-120 is delivered by stereotactic injection to the affected area of the brain, providing stable, long-lasting expression of NTN in a highly targeted fashion. Genzyme Corporation has licensed the ex-North American rights for the development and commercialization of CERE-120 from Ceregene, an agreement that was announced
'/>"/>

SOURCE Ceregene, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Ceregene Appoints Joao Siffert, M.D. to the Position of Chief Medical Officer
2. Ceregene Announces Two Key Additions to Leadership Team
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
5. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
6. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
7. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
8. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... SoundConnect , an award ... proud to announce the addition of Adobe Connects ... elearning tools to quickly deploy and manage online ... tools for desktop and mobile learning solutions. , ... perfect online training solution, enabling organizations to deploy, ...
(Date:7/31/2014)... 2014 The Kidney Cancer Association (KCA) has ... news magazine, Kidney Cancer News. , Bill Bro, KCA ... website maintained by an international news organization. When we began ... viewers.” , This month’s program highlights news of an enzyme ... in a recent study. Kidney Cancer News also presents a ...
(Date:7/31/2014)... 2014 Boston’s Adult Stem Cell Technology ... innovative adult stem cell biotechnologies. Currently the company ... three additional patent applications currently under examination by the ... address two of the most vexing problems in adult ... stem cells are difficult to identify; and they have ...
(Date:7/31/2014)... AZ (PRWEB) July 31, 2014 Sales ... availability of its online sales training course – ... improve their sales performance. , Drawn from proven sales ... 500 companies, Mastering the Complex Sale online sales training ... to anyone who has face-to-face contact with customers, like ...
Breaking Biology Technology:SoundConnect Enhances Portfolio with Adobe Connect Learning Management System (LMS) 2The Adult Stem Cell Technology Center, LLC Launches A Marketing Campaign To License Adult Stem Cell Biotechnologies 2The Adult Stem Cell Technology Center, LLC Launches A Marketing Campaign To License Adult Stem Cell Biotechnologies 3Sales Horizons Offers Mastering the Complex Sale - a Comprehensive, Online Sales Skills Training Course 2Sales Horizons Offers Mastering the Complex Sale - a Comprehensive, Online Sales Skills Training Course 3
... of articles on developing start-up companies in the technology or ... - You've started your new company, named it, and perhaps ... need additional funding, what other choices do you have? Before ... , ,Most of us recognize that we must have ...
... fast becoming one of the most sought-after spokesmen on behalf ... chief information officers and others will have plenty of prospective ... staff openings. , ,Tim Jump, who will speak at ... in Milwaukee, is a pre-engineering teacher by trade, and ...
... CDW Corp . has signed a definitive merger agreement ... equity firm Madison Dearborn Partners , which has endorsed ... a conference call with investors, CDW chief executive officer John ... growth strategies, including a planned expansion of the Berbee platform. ...
Cached Biology Technology:Early Stage: Step 11 - Other forms of finance 2Early Stage: Step 11 - Other forms of finance 3Early Stage: Step 11 - Other forms of finance 4Jump starting technology education 2Jump starting technology education 3CDW buyer supports Berbee growth plans 2
(Date:7/30/2014)... the way for a breakthrough that may prevent ... to poisonous chemicalsparticularly those in pesticides and chemical ... issue of the journal ChemBioChem outlines ... commonly used in pesticides and warfare agents. The ... Engineering Associate Professor of Chemical and Biological Engineering ...
(Date:7/30/2014)... truffle uses reversible epigenetic processes to regulate its genes, ... - a picture of the genome regulation taking place ... journal Genome Biology and illustrates how the ... ,jumping genes,. The authors say this may shed light ... , Black truffles (Tuber melanosporum), also known as Prigord ...
(Date:7/30/2014)... Red Queen in Lewis Carroll,s Through the Looking ... National University of Singapore improved a 35-year-old ecology ... decades to millions of years. , The new ... incorporates the "Red Queen Effect," an evolutionary hypothesis ... which suggests that organisms must constantly increase their ...
Breaking Biology News(10 mins):Engineering a protein to prevent brain damage from toxic agents 2How black truffles deal with the jumpers in their genome 2Classic Lewis Carroll character inspires new ecological model 2Classic Lewis Carroll character inspires new ecological model 3
... virus previously used as a marker in tracing human ... State. Results of this study also suggest that some ... than previously thought. , "The most genetically divergent human ... researcher at Penn State's Center for Infectious Disease Dynamics. ...
... Baptist Medical Center and colleagues at four other medical ... identify genes that may contribute to early atherosclerosis. ... and early adult life who have a genetic predisposition ... for heart disease and stroke sooner and more aggressively," ...
... In a new twist on the slogan “milk does ... staple as a contrast agent in gastrointestinal imaging exams—with ... the annual meeting of the Radiological Society of North ... bowel distension and enhancement as we see with the ...
Cached Biology News:Viral marker of human migration suspect 2Scientists work to identify genes that contribute to early heart attack risk 2Got inexpensive contrast agent? Milk plays new role in imaging 2
Mouse anti-IkBa/MAD-3 Class: Antibody Product Group: Signalling molecules and phospho-specific Antibody...
PI/RNase Staining Buffer Solution , 100 ml Consult technical datasheet for details....
Macrophage-stimulating protein receptor...
Mouse monoclonal [3B6] to HSV1 + HSV2 ICP5 Major Capsid Protein ( Abpromise for all tested applications)....
Biology Products: